Home>Topics>Stocks>Athersys

Athersys

  1. All
  2. Commentary
  1. Dropping Coverage of Athersys

    Commentary

    Fri, 13 Jan 2012

    We are no longer providing equity research on Athersys ATHX . We provide broad coverage of more than 1,700 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.

  2. Athersys Announces Partnership Changes, New Financing Deal

    Commentary

    Mon, 14 Nov 2011

    estimate intact after reviewing Athersys ' ATHX third-quarter results, a business ..... and financing arrangements. Athersys turned in a net loss of $2.3 ..... sheet. To buoy its cash balance, Athersys has entered into an equity purchase

  3. Athersys Under Review as Falling Stock Price Limits Firm's Ability to Raise Capital

    Commentary

    Mon, 8 Aug 2011

    We are putting Athersys ATHX under review in the wake of the company's plummeting share price. Athersys is a development-stage biotech with minimal revenue and negative profits, and equity issuances are key to the firm's survival as it burns

  4. Athersys' MultiStem Shows Activity in Early Stage Trials

    Commentary

    Fri, 22 Jul 2011

    We are maintaining our fair value estimate for Athersys ATHX after reviewing the company's progress over the past ..... MultiStem's assigned probability of approval. In May, Athersys announced positive interim results from an ongoing Phase

  5. MultiStem's Development Pushes Forward, but Much Risk Remains for Athersys

    Commentary

    Wed, 16 Feb 2011

    Athersys ATHX continues to advance its flagship stem ..... unknown about its safety and effectiveness. Athersys has completed enrollment of its Phase ..... and severity of the disease, for which Athersys received orphan drug designation for MultiStem

  6. Athersys Commences Its First Ever Midstage Trial for MultiStem

    Commentary

    Tue, 9 Nov 2010

    Along with its partner Pfizer PFE, Athersys ATHX announced that it will advance ..... importance for the potential of Athersys ' technology. However, the drug ..... the end of the third quarter, Athersys had $17.8 million in cash and

  7. ATHX Reports Promising Phase I Data

    Commentary

    Thu, 29 Jul 2010

    Athersys ATHX , along with partner Angiotech Pharmaceuticals ANPI , announced positive ..... the product is still in very early - stage development . In the trial , Athersys administered MultiStem to individuals following an episode of acute myocardial

Content Partners